# Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint

- Source: PR Newswire M&A
- Published: 2026-11-02T09:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-announces-commercialization-collaboration-with-simcere-for-zemprocitinib-in-dermatology-indications-further-expanding-product-commercialization-footprint-302926186.html
- Canonical: https://groundlevelnews.com/story/lynk-pharmaceuticals-announces-commercialization-collaboration-with-si-59f0b2/

HANGZHOU, China, SHANGHAI and BOSTON, Nov. 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), today announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Group Limited ("Simcere") for zemprocitinib, a highly selective,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._